Stock AMLX AMYLYX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Amylyx Pharmaceuticals, Inc.

Equities

AMLX

US03237H1014

Market Closed - Nasdaq
Other stock markets
 21:00:00 25/06/2024 BST 		5-day change 1st Jan Change
1.85 USD +1.09% Intraday chart for Amylyx Pharmaceuticals, Inc. +14.20% -87.43%
06-24 Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from S&P Pharmaceuticals Select Industry Index CI
06-21 Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar RE

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
RE
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Amylyx Pharmaceuticals Announces Interim Data from Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading
MT
Top Midday Stories: Ford Delays Start of EV Production at Canadian Plant; Alphabet Mulls Acquiring HubSpot; Boeing Paid Alaska Airlines $160 Million in Q1 for Fleet Grounding; Taiwan Semiconductor Expects Full Recovery of Top Plant on Thursday; Coinbase Registered as Restricted Dealer in Canada; CSX Completes First Shipments Using New Rail Post Baltimore Bridge Collapse; Levi Shares Soar on Earnings Beat; Amylyx to Discontinue Marketing Authorizations for Relyvrio
MT
Amylyx Pharmaceuticals, Inc. Announces Formal Intention to Remove Relyvrio/Albriza from the Market
CI
North American Morning Briefing : Inflation Data -2-
DJ
North American Morning Briefing : Stock Futures -2-
DJ
Health Care Flat After Trial Setbacks -- Health Care Roundup
DJ
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Ahead of Key Jobs Report
MT
Amylyx Pharmaceuticals, Inc. Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
CI
Amylyx Pharmaceuticals Swings to Q4 Profit, Net Product Revenue Increases; Shares Rise
MT
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 Orion Study of Amx0035 in Progressive Supranuclear Palsy
CI
Amylyx Pharmaceuticals, Inc. Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
CI
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Amylyx Pharmaceuticals, Inc. Announces to Present Clinical Trial Design of ORION, Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy, at Neuro2023 PSP and CBD International Research Symposium
CI
Amylyx Pharmaceuticals Says European Medicines Agency Panel Reaffirmed Negative Opinion on Amyotrophic Lateral Sclerosis Drug
MT
Amylyx Pharmaceuticals, Inc. Receives Negative Chmp Opinion on Its Marketing Authorisation Application for Amx0035 for the Treatment of Als in the European Union Following Re-Examination Process
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMLX Stock
  4. News Amylyx Pharmaceuticals, Inc.
  5. Highlights